First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Bobo Zheng
Xin Wang
Mingtian Wei
Quan Wang
Jiang Li
Liang Bi
Xiangbing Deng
Ziqiang Wang
机构：
[1] Sichuan University,Department of Gastrointestinal Surgery, West China Hospital
[2] First Affiliated Hospital of Xi’an Jiaotong University,Department of Gastroenterology
[3] The Fourth Military Medical University,Digestive disease hospital, Xijing Hospital
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,National Cancer Center/Cancer Hospital
来源：
BMC Cancer | / 19卷
关键词：
First line; Cetuximab; Bevacizumab; Wild type; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [32] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [33] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
  • [34] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
    Gherardi, A.
    Masia, C.
    Plommet, N.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
  • [35] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [36] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [37] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [38] Cost-utility analysis of panitumumab use compared with cetuximab and bevacizumab for the first-line therapy of wild-type RAS metastatic colorectal cancer in the Peruvian health system.
    Milton, Valderrama
    Apolaya-Segura, Moises
    Montenegro, Paola Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer A meta-analysis
    Yang, Ya-Fan
    Wang, Gui-Ying
    He, Jing-Li
    Wu, Feng-Peng
    Zhang, Yan-Ni
    MEDICINE, 2017, 96 (12)
  • [40] Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy
    Klein-Scory, S.
    Wahner, I.
    Maslova, M.
    Al-Sewaidi, Y.
    Pohl, M.
    Mika, T.
    Ladigan, S.
    Schroers, R.
    Baraniskin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S229 - S229
12345